NEW YORK, March 28, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/gern.
The investigation concerns whether Geron and certain of its officers and/or directors have violated Federal Securities Laws.
On March 27, 2017, Adam Feuerstein, writing for STAT, published a report stating that the Company's recent stock performance was due to "flimsy" claims with respect to the efficacy of imetelstat, Geron's experimental myelofibrosis treatment. Feuerstein asserted that the available data for imetelstat undercuts Geron's representations as to the drug's efficacy. On this news, Geron's share price fell $0.83, or 13.88%, to close at $5.15 on March 27, 2018.
If you are aware of any facts relating to this investigation, or purchased Geron shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/gern. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | firstname.lastname@example.org
SOURCE Bronstein, Gewirtz & Grossman, LLC